BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16304368)

  • 1. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ottmann OG; Wassmann B
    Hematology Am Soc Hematol Educ Program; 2005; ():118-22. PubMed ID: 16304368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.
    Thomas DA
    Hematology Am Soc Hematol Educ Program; 2007; ():435-43. PubMed ID: 18024662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
    Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
    Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
    Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
    Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.
    Tiribelli M; Sperotto A; Candoni A; Simeone E; Buttignol S; Fanin R
    Leuk Res; 2009 Jan; 33(1):174-7. PubMed ID: 18471874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
    Czyz A; Lewandowski K; Kroll R; Komarnicki M
    Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib for relapsed BCR/ABL positive leukemias.
    Ottmann OG; Wassmann B; Hoelzer D
    Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
    Leoni V; Biondi A
    Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
    [No Abstract]   [Full Text] [Related]  

  • 13. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Stock W
    Leuk Lymphoma; 2010 Feb; 51(2):188-98. PubMed ID: 20001232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fielding AK
    Blood; 2010 Nov; 116(18):3409-17. PubMed ID: 20656928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
    Swords R
    Drugs; 2007; 67(17):2655-6. PubMed ID: 18034599
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Thomas X; Dombret H
    Leuk Lymphoma; 2008 Jul; 49(7):1246-54. PubMed ID: 18452076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
    Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
    Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Gruber F; Mustjoki S; Porkka K
    Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
    Chang BH; Willis SG; Stork L; Hunger SP; Carroll WL; Camitta BM; Winick NJ; Druker BJ; Schultz KR
    Br J Haematol; 2012 May; 157(4):507-10. PubMed ID: 22299775
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.